234 related articles for article (PubMed ID: 35696229)
1. New psychoactive substances in Taiwan: The current situation and initiative for rational scheduling.
Yu WJ; Cottler L; Li JH
J Food Drug Anal; 2021 Mar; 29(1):168-181. PubMed ID: 35696229
[TBL] [Abstract][Full Text] [Related]
2. New psychoactive substances in Taiwan: challenges and strategies.
Feng LY; Li JH
Curr Opin Psychiatry; 2020 Jul; 33(4):306-311. PubMed ID: 32167950
[TBL] [Abstract][Full Text] [Related]
3. Emergency department visits due to new psychoactive substances and other illicit drugs in Taiwan: preliminary results of the Taiwan Emergency Department Drug Abuse Surveillance (TEDAS) project.
Lin CC; Weng TI; Ng CJ; Shih CP; Hsu J; Liao YC; Yang CC; Fang CC;
Clin Toxicol (Phila); 2022 Jun; 60(6):708-715. PubMed ID: 35315299
[TBL] [Abstract][Full Text] [Related]
4. Prevalence of cathinones and other new psychoactive substances in hair of parents and children of families with known or suspected parental abuse of conventional illegal drugs.
Niebel A; Pragst F; Krumbiegel F; Hartwig S
Forensic Sci Int; 2022 Feb; 331():111148. PubMed ID: 34923263
[TBL] [Abstract][Full Text] [Related]
5. Comparison of legislative management for new psychoactive substances control among Taiwan, South Korea, and Japan.
Feng LY; Wada K; Chung H; Han E; Li JH
Kaohsiung J Med Sci; 2020 Feb; 36(2):135-142. PubMed ID: 31643137
[TBL] [Abstract][Full Text] [Related]
6. Self-reported use of novel psychoactive substances in a US nationally representative survey: Prevalence, correlates, and a call for new survey methods to prevent underreporting.
Palamar JJ; Martins SS; Su MK; Ompad DC
Drug Alcohol Depend; 2015 Nov; 156():112-119. PubMed ID: 26377051
[TBL] [Abstract][Full Text] [Related]
7. [Use of synthetic substances in France and in Europe].
Debruyne D; Monzon E; Perino J; Haramburu F; Daveluy A; Lazès-Charmetant A; Giraudon I
Therapie; 2021; 76(3):221-228. PubMed ID: 32859404
[TBL] [Abstract][Full Text] [Related]
8. Comparison of illegal drug use pattern in Taiwan and Korea from 2006 to 2014.
Feng LY; Yu WJ; Chang WT; Han E; Chung H; Li JH
Subst Abuse Treat Prev Policy; 2016 Sep; 11(1):34. PubMed ID: 27663984
[TBL] [Abstract][Full Text] [Related]
9. Differences between users' and addiction medicine experts' harm and benefit assessments of licit and illicit psychoactive drugs: Input for psychoeducation and legalization/restriction debates.
Bonnet U; Specka M; Kanti AK; Scherbaum N
Front Psychiatry; 2022; 13():1041762. PubMed ID: 36465301
[TBL] [Abstract][Full Text] [Related]
10. Festivals following the easing of COVID-19 restrictions: Prevalence of new psychoactive substances and illicit drugs.
Rousis N; Bade R; Romero-Sánchez I; Mueller JF; Thomaidis NS; Thomas KV; Gracia-Lor E
Environ Int; 2023 Aug; 178():108075. PubMed ID: 37399770
[TBL] [Abstract][Full Text] [Related]
11. [Weighing the benefits and harms of psychotropic and analgesic substances - A perspective of German addiction medicine experts].
Bonnet U; Specka M; Soyka M; Alberti T; Bender S; Hilger J; Hillemacher T; Kuhlmann T; Kuhn J; Lüdecke C; Reimer J; Schneider U; Schroeder W; Stuppe M; Wiesbeck G; Wodarz N; Scherbaum N
Fortschr Neurol Psychiatr; 2022 Jan; 90(1-02):19-29. PubMed ID: 33634461
[TBL] [Abstract][Full Text] [Related]
12. A systematic review of the effects of novel psychoactive substances 'legal highs' on people with severe mental illness.
Gray R; Bressington D; Hughes E; Ivanecka A
J Psychiatr Ment Health Nurs; 2016 Jun; 23(5):267-81. PubMed ID: 27037639
[TBL] [Abstract][Full Text] [Related]
13. Self-reported use of novel psychoactive substances among attendees of electronic dance music venues.
Palamar JJ; Acosta P; Sherman S; Ompad DC; Cleland CM
Am J Drug Alcohol Abuse; 2016 Nov; 42(6):624-632. PubMed ID: 27315522
[TBL] [Abstract][Full Text] [Related]
14. Scheduling of new psychoactive substance the Swiss way: A review and critical analysis.
Grafinger KE; Bernhard W; Weinmann W
Sci Justice; 2019 Jul; 59(4):459-466. PubMed ID: 31256819
[TBL] [Abstract][Full Text] [Related]
15. New Psychoactive Substances and Suicidality: A Systematic Review of the Current Literature.
Chiappini S; Mosca A; Miuli A; Santovito MC; Orsolini L; Corkery JM; Guirguis A; Pettorruso M; Martinotti G; Di Giannantonio M; Schifano F
Medicina (Kaunas); 2021 Jun; 57(6):. PubMed ID: 34204131
[No Abstract] [Full Text] [Related]
16. Monitoring psychoactive substance use at six European festivals through wastewater and pooled urine analysis.
Bijlsma L; Celma A; Castiglioni S; Salgueiro-González N; Bou-Iserte L; Baz-Lomba JA; Reid MJ; Dias MJ; Lopes A; Matias J; Pastor-Alcañiz L; Radonić J; Turk Sekulic M; Shine T; van Nuijs ALN; Hernandez F; Zuccato E
Sci Total Environ; 2020 Jul; 725():138376. PubMed ID: 32298891
[TBL] [Abstract][Full Text] [Related]
17. Polysubstance use profiles among electronic dance music party attendees in New York City and their relation to use of new psychoactive substances.
Fernández-Calderón F; Cleland CM; Palamar JJ
Addict Behav; 2018 Mar; 78():85-93. PubMed ID: 29128711
[TBL] [Abstract][Full Text] [Related]
18. New psychoactive substances in Eurasia: a qualitative study of people who use drugs and harm reduction services in six countries.
Kurcevič E; Lines R
Harm Reduct J; 2020 Nov; 17(1):94. PubMed ID: 33256747
[TBL] [Abstract][Full Text] [Related]
19. The clinical challenges of synthetic cathinones.
Schifano F; Napoletano F; Arillotta D; Zangani C; Gilgar L; Guirguis A; Corkery JM; Vento A
Br J Clin Pharmacol; 2020 Mar; 86(3):410-419. PubMed ID: 31674690
[TBL] [Abstract][Full Text] [Related]
20. Recreational use, analysis and toxicity of tryptamines.
Tittarelli R; Mannocchi G; Pantano F; Romolo FS
Curr Neuropharmacol; 2015 Jan; 13(1):26-46. PubMed ID: 26074742
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
